Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Current therapies for metabolic diseases Inborn errors
2023-03-08

Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
In the search for more specific inhibitors
2023-03-08

In the search for more specific inhibitors of uptake2, Iversen and Salt (1970) speculated that steroids may potentiate the actions of catecholamines on vascular smooth muscle by inhibiting uptake2-mediated catecholamine clearance of the transmitters. They went on to demonstrate that a variety of ste
-
br ABCA modulates intracellular sphingolipid metabolism in t
2023-03-08

ABCA2 modulates intracellular sphingolipid metabolism in the LE/LY Recycling of plasma membrane lipids that occurs by constitutive endocytosis and vesicularization of complex glycolipids, complex sphingolipids and cholesterol as well as free cholesterol liberated from LDL after receptor-mediated
-
br Conflict of Interest br Transparency Document br
2023-03-08

Conflict of Interest Transparency Document Introduction Mitoxantrone (MXT) is an androstenedione chemotherapeutic agent that is used to treat acute nonlymphocytic leukemia, acute lymphoblastic leukemia, prostate cancer, metastatic breast cancer, and non-Hodgkin’s lymphoma [13], [14]. It is
-
Although we have achieved a great deal of success
2023-03-07

Although we have achieved a great deal of success in the development of tools to understand autophagy in health and disease, highly specific reagents for autophagy manipulation and deep knowledge of autophagy is required to advance the research in therapeutic treatment. Better disease (ischemia) ani
-
Camptothecin receptor Suspecting that ACL might regulate the
2023-03-06

Suspecting that ACL might regulate the expression or activity of myogenic transcription factors, Das knocked down MyoD and found that such intervention abolished the effect of ACL on fast MyHC expression and that, conversely, MyoD overexpression partially rescued reduced fast MyHC expression caused
-
Exposure to cisplatin with ATR inhibitor resulted in
2023-03-06

Exposure to cisplatin with ATR inhibitor resulted in an increase in cisplatin-DNA adducts, especially in cells with ATM deficiency. This finding indicates that suppressing ATR-Chk1 signaling with VE-822 enhances cisplatin activity by enabling the drug to form DNA adducts. Therefore, VE-822 may incre
-
A previous review article suggested different washout interv
2023-03-06

A previous review article suggested different washout intervals based on specific clinical contexts [4]. While no consensus was reached for the optimal interval between last dose of BV and surgery for CRLM, the authors of the review suggested waiting 6 to 8 weeks after BV before surgery, particularl
-
A Venn diagram representing RNA seq data
2023-03-06

A. Venn diagram representing RNA-seq data that show the number of gene overlaps in GFP and HepKO livers after chronic PF-06409577 dosing. B. Top canonical pathways that changed according to Ingenuity Pathway Analysis after chronic PF-06409577 dosing. C. Fibrosis-related genes that were altered in GF
-
YM 155 Perhaps the first evidence of AMPKs therapeutic abili
2023-03-06

Perhaps the first evidence of AMPKs therapeutic ability in DM1 came from Thomas Cooper’s laboratory where they demonstrated that insulin-independent glucose uptake was unaffected in human DM1 muscle YM 155 treated with MET, an AMPK activator and first-line therapy for type 2 diabetes mellitus [76].
-
Our research group has been involved by many
2023-03-06

Our research group has been involved by many years in the synthesis of new 2,3-benzodiazepin-4-ones (e.g. 1, Fig. 1) and in the characterization of their mechanism of action.15, 16, 17 Within the development of these compounds, we demonstrated that an improvement of AMPAR antagonism by 2,3-benzodiaz
-
In conclusion phenolic hydroxyl was
2023-03-06

In conclusion, phenolic hydroxyl was introduced not only to C3 side chain but also to C6 or C7 position of the quinoxalinone core, resulting in a new group of ARIs candidates exhibiting antioxidant activity. Biological activity tests suggested that compounds were not only sufficient to inhibit ALR2
-
It is important to note that stable amnesia is apparently
2023-03-06

It is important to note that stable amnesia is, apparently, a general biological phenomenon and can be found in different animal species. In studies on rats, it was found that if reconsolidation of conditioned olfactory aversion memory was impaired by the antagonist of NMDA glutamate receptors, amne
-
The CK catalyzes the reversible conversion of
2023-03-06

The CK catalyzes the reversible conversion of creatine into creatine phosphate using ATP and thereby releasing ADP. The CK isoenzymes, specifically localized in places where there is a demand and production of energy, are linked to a creatine/creatine phosphate shuttle (Wallimann et al., 1998). This
-
In the previous study we
2023-03-03

In the previous study, we demonstrated the importance of the mPFC postsynaptic 5-HT1A receptor in the sustained antidepressant effects, because a sustained antidepressant effect was obtained with intra-mPFC injection, but not systemic injection of 8-OH-DPAT, a 5-HT1A receptor agonist (Fukumoto et al
16364 records 376/1091 page Previous Next First page 上5页 376377378379380 下5页 Last page